These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25216746)

  • 1. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
    Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
    Liang Y; Arakawa K; Ueta K; Matsushita Y; Kuriyama C; Martin T; Du F; Liu Y; Xu J; Conway B; Conway J; Polidori D; Ways K; Demarest K
    PLoS One; 2012; 7(2):e30555. PubMed ID: 22355316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
    Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
    Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
    Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
    Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
    Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
    Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
    Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
    Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
    Shibazaki T; Tomae M; Ishikawa-Takemura Y; Fushimi N; Itoh F; Yamada M; Isaji M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):288-96. PubMed ID: 22537769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
    Fujimori Y; Katsuno K; Ojima K; Nakashima I; Nakano S; Ishikawa-Takemura Y; Kusama H; Isaji M
    Eur J Pharmacol; 2009 May; 609(1-3):148-54. PubMed ID: 19281809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.
    Adachi T; Yasuda K; Okamoto Y; Shihara N; Oku A; Ueta K; Kitamura K; Saito A; Iwakura I; Yamada Y; Yano H; Seino Y; Tsuda K
    Metabolism; 2000 Aug; 49(8):990-5. PubMed ID: 10954015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
    Takasu T; Takakura S
    Biol Pharm Bull; 2018; 41(5):761-769. PubMed ID: 29709913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
    Jurczak MJ; Lee HY; Birkenfeld AL; Jornayvaz FR; Frederick DW; Pongratz RL; Zhao X; Moeckel GW; Samuel VT; Whaley JM; Shulman GI; Kibbey RG
    Diabetes; 2011 Mar; 60(3):890-8. PubMed ID: 21357472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
    Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
    J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle.
    O'Brien TP; Jenkins EC; Estes SK; Castaneda AV; Ueta K; Farmer TD; Puglisi AE; Swift LL; Printz RL; Shiota M
    Diabetes; 2017 May; 66(5):1172-1184. PubMed ID: 28246292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.
    Li S; Wang N; Guo X; Li J; Zhang T; Ren G; Li D
    Biomed Pharmacother; 2018 Dec; 108():355-366. PubMed ID: 30227329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
    Trevaskis JL; Sacramento CB; Jouihan H; Ali S; Le Lay J; Oldham S; Bhagroo N; Boland BB; Cann J; Chang Y; O'Day T; Howard V; Reers C; Winzell MS; Smith DM; Feigh M; Barkholt P; Schreiter K; Austen M; Andag U; Thompson S; Jermutus L; Coghlan MP; Grimsby J; Dohrmann C; Rhodes CJ; Rondinone CM; Sharma A
    Diabetes; 2017 Jul; 66(7):2007-2018. PubMed ID: 28408435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.